This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

EClinical Provider DATATRAK Joins SAS® Alliance To Offer Cloud-Based SAS® Drug Development

CLEVELAND, June 19, 2013 /PRNewswire/ --  DATATRAK International, Inc. (OTCQX: DTRK), a leader in developing cloud-based, unified eClinical® technologies and delivering related services for the clinical trials industry, today announced their partnership with SAS to provide SAS® Drug Development as an extension of the D ATATRAK ONE™ solution.

(Logo: http://photos.prnewswire.com/prnh/20130107/CL38347LOGO)

"As the innovator in cloud-based eClinical solutions, D ATATRAK brings the power of SAS Drug Development to customers with our rapid integration capabilities," stated Laurence P. Birch, D ATATRAK's Chairman of the Board and CEO. " D ATATRAK customers already enjoy real-time access to all of their study data with our unified platform. Adding SAS Drug Development to our arsenal gives users the power of SAS Analytics across all their unified data, accelerating the drug development process through greater data visibility and real-time analysis."

Aimed at transforming clinical research processes through repeatable, sustainable improvements, D ATATRAK will work with SAS to make SAS Drug Development available in the cloud, providing data flow from D ATATRAK ONE™ into SAS Drug Development. The seamless integration is designed to streamline work processes for a company-wide implementation across the breadth of a drug development program. Intended to support Clinical Data Interchange Standards Consortium (CDISC) standards, the integrated cloud-based solution will be designed to leverage D ATATRAK's unified platform with workflows, document management, and analysis to support the current needs and future business growth of life sciences organizations.

SAS Drug Development helps organizations make informed clinical and business decisions; streamline and optimize analysis and reporting processes; assess safety and efficacy more effectively; and improve collaboration with business partners and regulatory authorities. It eases analysis and reporting for single trials as well as aggregated clinical data assets across multiple trials or therapies.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,579.96 -109.90 -0.62%
S&P 500 2,094.44 -9.40 -0.45%
NASDAQ 5,107.34 -20.9410 -0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs